Research Data from Third Military Medical University Update Understanding of Lung Cancer (Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Lung Cancer. According to news originating from Chongqing, People's Republic of China, by NewsRx correspondents, research stated, "Curcumin, a dietary supplement or herbal medicine from Curcuma longa, has shown antitumor activity in different cancer cell lines and clinical trials. CA916798, a novel protein, is overexpressed in multidrug-resistant tumor cells."
Financial support for this research came from Chinese National Science Foundation (see also Oncology - Lung Cancer).
Our news journalists obtained a quote from the research from Third Military Medical University, "This study aimed to assess the effects of curcumin on regulating chemosensitivity in cisplatin-resistant non-small cell lung cancer (NSCLC) cells in vitro and to explore the underlying molecular mechanisms. Human cisplatin-sensitive A549 and cisplatin-resistant A549/CDDP lung adenocarcinoma cells were treated with curcumin to assess cell viability and gene modulations using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. CA916798 shRNA and point mutations were used to assess the CA916798 functions and phosphorylation sites. Bisdemethoxycurcumin sensitized cisplatin-resistant lung cancer cells to various chemotherapeutic agents, including cisplatin. Bisdemethoxycurcumin reduced the levels of CA916798 mRNA and protein in A549 and A549/CDDP cells, while it also suppressed phosphatidylinositol-3-kinase (PI3K)/AKT signaling. CA916798, as a downstream gene, interacted with AKT after bisdemethoxycurcumin treatment in A549 and A549/CDDP cells. Moreover, A549/CDDP cells expressing the point-mutated CA916798-S20D protein were more resistant to cisplatin and bisdemethoxycurcumin, whereas tumor cells expressing CA916798-S20A, CA916798-S31A, CA916798-S60A, CA916798-S93A, or CA916798-T97A (different sites of amino acid phosphorylation) showed similar sensitivity or resistance to cisplatin and bisdemethoxycurcumin, compared with the control cells. Bisdemethoxycurcumin is able to sensitize cisplatin-resistant NSCLC cells to chemotherapeutic agents by inhibition of CA916798 and PI3K/AKT activities."
According to the news editors, the research concluded: "Moreover, phosphorylation of CA916798 at the S20 residue plays a critical role in mediating bisdemethoxycurcumin antitumor activity."
For more information on this research see: Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Apoptosis, 2017;22(9):1157-1168. Apoptosis can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Apoptosis - www.springerlink.com/content/1360-8185/)
The news correspondents report that additional information may be obtained from X.D. Zhou, Third Military Medical University, Southwest Hosp, Dept. of Resp Med, Chongqing, People's Republic of China. Additional authors for this research include Z.X. Yang, X.T. Dai, Y.F. Chen, H.P. Yang and H.J. Wang.
Keywords for this news article include: Chongqing, People's Republic of China, Asia, Drugs and Therapies, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds, Lung Neoplasms, Chemotherapy, Lung Cancer, Cisplatin, Oncology, Genetics, Third Military Medical University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC